Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab.

[1]  S. Signoretti,et al.  Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.

[2]  R. Motzer,et al.  Associations between body composition features and clinical outcomes in metastatic clear cell renal cell carcinoma patients treated with immune checkpoint blockade. , 2022, Clinical Cancer Research.

[3]  Said Pertuz,et al.  Methodology, clinical applications, and future directions of body composition analysis using computed tomography (CT) images: A review. , 2021, European journal of radiology.

[4]  V. Master,et al.  Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors , 2021, Frontiers in Oncology.

[5]  T. Choueiri,et al.  Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. , 2021, JAMA oncology.

[6]  Shannon K. Boi,et al.  Obesity diminishes response to PD-1-based immunotherapies in renal cancer , 2020, Journal for ImmunoTherapy of Cancer.

[7]  S. Hancock,et al.  NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  Mirza Faisal Beg,et al.  Deep learning method for localization and segmentation of abdominal CT , 2020, Comput. Medical Imaging Graph..

[9]  H. Lau,et al.  A Systematic Review and Meta-Analysis of the Significance of Body Mass Index on Kidney Cancer Outcomes. , 2020, The Journal of urology.

[10]  G. Valabrega,et al.  Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy , 2020, International journal of molecular sciences.

[11]  J. Meyerhardt,et al.  Evaluation of automated computed tomography segmentation to assess body composition and mortality associations in cancer patients , 2020, Journal of cachexia, sarcopenia and muscle.

[12]  R. Motzer,et al.  Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. , 2019, The Lancet. Oncology.

[13]  E. Giovannucci,et al.  The Obesity Paradox in Cancer: Epidemiologic Insights and Perspectives , 2019, Current Nutrition Reports.

[14]  L. Crinò,et al.  Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab , 2019, Clinical Cancer Research.

[15]  E. Philip,et al.  Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma , 2019, Kidney Cancer.

[16]  Justin C. Brown,et al.  The evolution of body composition in oncology—epidemiology, clinical trials, and the future of patient care: facts and numbers , 2018, Journal of cachexia, sarcopenia and muscle.

[17]  B. Tan,et al.  Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis , 2018, Gastric Cancer.

[18]  B. Escudier,et al.  Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma , 2018, Drugs.

[19]  B. Caan,et al.  The Obesity Paradox in Cancer: How Important Is Muscle? , 2018, Annual review of nutrition.

[20]  B. Caan,et al.  The Importance of Body Composition in Explaining the Overweight Paradox in Cancer-Counterpoint. , 2018, Cancer research.

[21]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[22]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[23]  L. Kiemeney,et al.  Body Composition in Relation to Clinical Outcomes in Renal Cell Cancer: A Systematic Review and Meta-analysis. , 2016, European urology focus.

[24]  D. Ye,et al.  Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients , 2017, Scientific Reports.

[25]  S. Signoretti,et al.  Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. Muss,et al.  Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. , 2016, European journal of cancer.

[27]  Martin Jägersand,et al.  Body Composition Assessment in Axial CT Images Using FEM-Based Automatic Segmentation of Skeletal Muscle , 2016, IEEE Transactions on Medical Imaging.

[28]  C. Prado,et al.  Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact , 2016, Proceedings of the Nutrition Society.

[29]  M. Kuczyk,et al.  Does overweight influence the prognosis of renal cell carcinoma? Results of a multicenter study , 2013, International journal of urology : official journal of the Japanese Urological Association.

[30]  H. Adami,et al.  Body mass index and survival in patients with renal cell carcinoma: A clinical‐based cohort and meta‐analysis , 2013, International journal of cancer.

[31]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[32]  L. Birdsell,et al.  Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[34]  R. Ross,et al.  Human body composition: advances in models and methods. , 1997, Annual review of nutrition.